share_log

Axsome Therapeutics Analyst Ratings

Benzinga Analyst Ratings ·  Sep 30, 2022 08:32
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/30/2022 60.82% Morgan Stanley $75 → $71 Maintains Equal-Weight
09/07/2022 72.14% Mizuho → $76 Assumes → Buy
08/30/2022 69.88% Morgan Stanley $55 → $75 Maintains Equal-Weight
08/23/2022 375.65% HC Wainwright & Co. $180 → $210 Maintains Buy
08/22/2022 69.88% SVB Leerink $50 → $75 Maintains Outperform
08/10/2022 24.58% Morgan Stanley $54 → $55 Maintains Equal-Weight
07/08/2022 22.31% Morgan Stanley $27 → $54 Maintains Equal-Weight
06/29/2022 194.45% Cowen & Co. $120 → $130 Maintains Outperform
06/29/2022 44.96% Cantor Fitzgerald $47 → $64 Maintains Overweight
05/03/2022 10.99% Mizuho $51 → $49 Maintains Buy
04/27/2022 -38.84% Morgan Stanley $34 → $27 Maintains Equal-Weight
03/29/2022 74.41% Jefferies $71 → $77 Maintains Buy
03/02/2022 13.25% SVB Leerink $65 → $50 Maintains Outperform
11/09/2021 47.23% SVB Leerink $75 → $65 Maintains Outperform
08/30/2021 307.7% HC Wainwright & Co. $225 → $180 Maintains Buy
08/10/2021 69.88% SVB Leerink $115 → $75 Maintains Outperform
08/10/2021 262.4% Truist Securities $200 → $160 Maintains Buy
08/10/2021 24.58% Mizuho $118 → $55 Maintains Buy
08/10/2021 -22.99% Morgan Stanley $105 → $34 Downgrades Overweight → Equal-Weight
06/10/2021 153.68% Berenberg → $112 Initiates Coverage On → Buy
05/26/2021 137.83% Morgan Stanley $104 → $105 Maintains Overweight
04/27/2021 409.63% HC Wainwright & Co. $210 → $225 Maintains Buy
03/02/2021 135.56% Morgan Stanley $101 → $104 Maintains Overweight
01/08/2021 192.19% Jefferies → $129 Initiates Coverage On → Buy
12/16/2020 171.8% Mizuho → $120 Initiates Coverage On → Buy
11/09/2020 128.77% Morgan Stanley $102 → $101 Maintains Overweight
09/29/2020 49.49% B of A Securities → $66 Initiates Coverage On → Underperform
09/10/2020 131.03% Morgan Stanley → $102 Initiates Coverage On → Overweight
04/28/2020 375.65% HC Wainwright & Co. $200 → $210 Maintains Buy
04/28/2020 196.72% Cantor Fitzgerald $125 → $131 Maintains Overweight
04/14/2020 115.18% Cowen & Co. → $95 Initiates Coverage On → Outperform
12/30/2019 183.13% Cantor Fitzgerald $104 → $125 Reiterates → Overweight
12/30/2019 353% HC Wainwright & Co. $170 → $200 Maintains Buy
12/16/2019 257.87% Guggenheim $65 → $158 Maintains Buy
12/16/2019 135.56% Cantor Fitzgerald $55 → $104 Maintains Overweight
10/16/2019 8.72% Guggenheim → $48 Initiates Coverage On → Buy
09/18/2019 William Blair Initiates Coverage On → Outperform
04/08/2019 -43.37% SVB Leerink → $25 Initiates Coverage On → Outperform
03/21/2019 -43.37% Cantor Fitzgerald $16 → $25 Maintains Overweight
11/15/2018 -63.76% Cantor Fitzgerald → $16 Reinstates → Overweight
06/07/2018 -77.35% HC Wainwright & Co. → $10 Initiates Coverage On → Buy

Axsome Therapeutics Questions & Answers

What is the target price for Axsome Therapeutics (AXSM)?

The latest price target for Axsome Therapeutics (NASDAQ: AXSM) was reported by Morgan Stanley on September 30, 2022. The analyst firm set a price target for $71.00 expecting AXSM to rise to within 12 months (a possible 60.82% upside). 14 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Axsome Therapeutics (AXSM)?

The latest analyst rating for Axsome Therapeutics (NASDAQ: AXSM) was provided by Morgan Stanley, and Axsome Therapeutics maintained their equal-weight rating.

When is the next analyst rating going to be posted or updated for Axsome Therapeutics (AXSM)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axsome Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axsome Therapeutics was filed on September 30, 2022 so you should expect the next rating to be made available sometime around September 30, 2023.

Is the Analyst Rating Axsome Therapeutics (AXSM) correct?

While ratings are subjective and will change, the latest Axsome Therapeutics (AXSM) rating was a maintained with a price target of $75.00 to $71.00. The current price Axsome Therapeutics (AXSM) is trading at is $44.15, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment